Should we be worried about Covid this winter?
Experts are not too concerned about a new variant of Covid but say monitoring should continue.
Similar Posts
These were some of the most potentially dangerous products recalled in 2023
Although U.S. consumers buy products on the assumption that they are safe, potentially dangerous items often make it past regulators and into retailers. In 2023, the year began and ended with recalls and warnings involving products that can be deadly for children. Here’s a look at some products recalled last year that consumers should be…
New COVID variant JN.1 now comprises up to 30% of US cases: CDC
The latest variant of the COVID-19 virus, JN.1, is now responsible for an estimated 15% to 29% of cases in the U.S. as of Dec. 8, according to a posted update from the Centers for Disease Control and Prevention (CDC). JN.1, which is currently the country’s fastest growing variant, is expected to continue to increase…
A new study finds high levels of nanoplastics in bottled water
A new study finds high levels of nanoplastics in bottled water – CBS News Watch CBS News New research finds large amounts of nanoplastics in bottled water. Dr. Celine Gounder, CBS News medical contributor and editor at large for Public Health at KFF, explains how to limit exposure to avoid potential health problems. Be the…
MoonLake Immunotherapeutics explores sale | Reuters News Agency
Business & FinanceDealsHealth 14 July 2023, 5:43 pm 1 minute MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition. Market Impact MoonLake’s shares ended trading up 8.4% at $54.27 on the news on Friday,…
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma, a drugmaker specializing in one of the hottest areas of cancer treatment….
